U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Salivary Gland Carcinoma

MedGen UID:
1785855
•Concept ID:
C5448100
•
Neoplastic Process

Definition

Salivary gland carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Salivary Gland Carcinoma

Professional guidelines

PubMed

Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article

Recent clinical studies

Etiology

Partial response to RC-48 as palliative treatment in a patient with locallocally advanced carcinoma ex pleomorphic adenoma harboring a HER2 mutation: a case report.
Yu W, Ding C, Li K
Oral Oncol 2023 Nov;146:106541. Epub 2023 Aug 16 doi: 10.1016/j.oraloncology.2023.106541. PMID: 37595449
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M
Oral Oncol 2022 Jul;130:105932. Epub 2022 May 27 doi: 10.1016/j.oraloncology.2022.105932. PMID: 35636078
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yew PY, Yoshimura S, Onishi H, Nakamura M, Nakamura Y, Morisaki T
Immunol Invest 2022 Jul;51(5):1498-1514. Epub 2021 Sep 5 doi: 10.1080/08820139.2021.1973491. PMID: 34486463
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia.
Bhayani MK, Acharya V, Kongkiatkamon S, Farah S, Roberts DB, Sterba J, Chambers MS, Lai SY
Thyroid 2015 Jul;25(7):834-8. Epub 2015 May 15 doi: 10.1089/thy.2014.0572. PMID: 25860842Free PMC Article

Diagnosis

A Rare Case of Primary Pulmonary Adenoid Cystic Carcinoma and the Diagnostic Challenges on Cytology.
White K, Askeland R, Bohy K
S D Med 2021 Jul;74(7):329-331. PMID: 34449997
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Refractory Facial Paralysis: A Case Report.
Hsu YW, Lee JT, Liao YS, Nieh S, Cheng CA, Tsai CK
Acta Neurol Taiwan 2017 Jun 15;26(2):68-71. PMID: 29250758
Microcystic adnexal carcinoma (MAC)-like squamous cell carcinoma as a differential diagnosis to Bell´s palsy: review of guidelines for refractory facial nerve palsy.
Mueller SK, Iro H, Lell M, Seifert F, Bohr C, Scherl C, Agaimy A, Traxdorf M
J Otolaryngol Head Neck Surg 2017 Jan 5;46(1):1. doi: 10.1186/s40463-016-0180-0. PMID: 28057072Free PMC Article
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article

Therapy

Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M
Oral Oncol 2022 Jul;130:105932. Epub 2022 May 27 doi: 10.1016/j.oraloncology.2022.105932. PMID: 35636078
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yew PY, Yoshimura S, Onishi H, Nakamura M, Nakamura Y, Morisaki T
Immunol Invest 2022 Jul;51(5):1498-1514. Epub 2021 Sep 5 doi: 10.1080/08820139.2021.1973491. PMID: 34486463
Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma.
Parag-Sharma K, Tasoulas J, Musicant AM, do Nascimento-Filho CHV, Zhu Z, Twomey C, Liu P, Castilho RM, Amelio AL
Oral Oncol 2021 Apr;115:105166. Epub 2021 Feb 11 doi: 10.1016/j.oraloncology.2020.105166. PMID: 33581505Free PMC Article
Pan-Cancer Efficacy of Vemurafenib in BRAF (V600)-Mutant Non-Melanoma Cancers.
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM
Cancer Discov 2020 May;10(5):657-663. Epub 2020 Feb 6 doi: 10.1158/2159-8290.CD-19-1265. PMID: 32029534Free PMC Article
Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia.
Bhayani MK, Acharya V, Kongkiatkamon S, Farah S, Roberts DB, Sterba J, Chambers MS, Lai SY
Thyroid 2015 Jul;25(7):834-8. Epub 2015 May 15 doi: 10.1089/thy.2014.0572. PMID: 25860842Free PMC Article

Prognosis

Partial response to RC-48 as palliative treatment in a patient with locallocally advanced carcinoma ex pleomorphic adenoma harboring a HER2 mutation: a case report.
Yu W, Ding C, Li K
Oral Oncol 2023 Nov;146:106541. Epub 2023 Aug 16 doi: 10.1016/j.oraloncology.2023.106541. PMID: 37595449
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E
Cell Death Dis 2022 Aug 5;13(8):678. doi: 10.1038/s41419-022-05133-9. PMID: 35931701Free PMC Article
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S, Li H, Lin Y, Xie Y, Yin Z, Ge W, Yu T
Anticancer Drugs 2022 Jan 1;33(1):e548-e554. doi: 10.1097/CAD.0000000000001171. PMID: 34321419Free PMC Article
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article

Clinical prediction guides

Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M
Oral Oncol 2022 Jul;130:105932. Epub 2022 May 27 doi: 10.1016/j.oraloncology.2022.105932. PMID: 35636078
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Pan-Cancer Efficacy of Vemurafenib in BRAF (V600)-Mutant Non-Melanoma Cancers.
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM
Cancer Discov 2020 May;10(5):657-663. Epub 2020 Feb 6 doi: 10.1158/2159-8290.CD-19-1265. PMID: 32029534Free PMC Article
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, Hirte HW
Ann Oncol 2006 Feb;17(2):334-40. Epub 2005 Nov 10 doi: 10.1093/annonc/mdj076. PMID: 16284058

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...